SEC Comment Letter 0000000000-24-014267 to INTENSITY THERAPEUTICS, INC. (INTS)
INTENSITY THERAPEUTICS, INC.
Date: Dec. 26, 2024 · CIK: 0001567264 · Accession: 0000000000-24-014267
AI Filing Summary & Sentiment
File numbers found in text: 001-41109
Referenced dates: October 28, 2021
Letter
December 26, 2024 Lewis H. Bender President & Chief Financial Officer INTENSITY THERAPEUTICS, INC. 1 Enterprise Drive Suite 430 Shelton, CT 06484 Re:INTENSITY THERAPEUTICS, INC. Form 10-K for the year ended December 31, 2023 Filed March 14, 2024 File No. 001-41109 Dear Lewis H. Bender: We have reviewed your filing and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe the comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K for the year ended December 31, 2023 Management's Discussion and Analysis of Financial Condition and Results of Operations Results of Operations , page 83 1.We note your disclosure on page F-9 that you track external research and development expenses based on research and development initiative, including preclinical, individual clinical study, and manufacturing activities but not by program. We also note the tabular disclosure of research and development expenses on page 48 of your Form S-1 amended on June 23, 2023, consistent with your response letter dated October 28, 2021. In this regard, please provide us in your response, revised disclosure of the costs incurred for the periods ended December 31, 2023 and nine- months ended September 30, 2024, for each of your key research and development initiatives which should reconcile to total research and development expense on the Statements of Operations. In addition, please provide similar revised disclosure in future periodic filings, beginning with your Form 10-K for the year ended December 31, 2024.
December 26, 2024 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Sasha Parikh at 202-551-3627 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
December 26, 2024
Lewis H. Bender
President & Chief Financial Officer
INTENSITY THERAPEUTICS, INC.
1 Enterprise Drive
Suite 430
Shelton, CT 06484
Re:INTENSITY THERAPEUTICS, INC.
Form 10-K for the year ended December 31, 2023
Filed March 14, 2024
File No. 001-41109
Dear Lewis H. Bender:
We have reviewed your filing and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe
the comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for the year ended December 31, 2023
Management's Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations , page 83
1.We note your disclosure on page F-9 that you track external research and
development expenses based on research and development initiative, including
preclinical, individual clinical study, and manufacturing activities but not by program.
We also note the tabular disclosure of research and development expenses on page 48
of your Form S-1 amended on June 23, 2023, consistent with your response letter
dated October 28, 2021. In this regard, please provide us in your response, revised
disclosure of the costs incurred for the periods ended December 31, 2023 and nine-
months ended September 30, 2024, for each of your key research and development
initiatives which should reconcile to total research and development expense on the
Statements of Operations. In addition, please provide similar revised disclosure in
future periodic filings, beginning with your Form 10-K for the year ended December
31, 2024.
December 26, 2024
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff.
Please contact Sasha Parikh at 202-551-3627 or Kevin Vaughn at 202-551-3494 if
you have questions regarding comments on the financial statements and related matters.
Sincerely,
Division of Corporation Finance
Office of Life Sciences